SEC Tracker
Get the app
CRMD · XBRL financial data

CorMedix financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CRMD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue———80611,456year only39,08239,737104,275128,615*——
Revenue from contracts with customers——————39,08239,736——127,427101,931
Cost of revenue——8195106871,176*1,5971,8627,56611,168*12,005—
Gross profit——(819)29610,770—37,48537,87493,081—105,12277,126
Research and development2,6642,289*8376517271,727*3,1922,4435,0988,600*7,2126,684
Selling, general and administrative7,80313,380*15,048—————————
General and administrative3,7455,220*8,7117,5596,5817,108*9,6939,50425,45123,572*21,72015,085
Total operating expenses10,46715,669*15,88615,59714,05717,098*17,36018,33141,73548,182*41,46434,216
Other operating income (expense)——————519806——(268)(71)
Operating income (loss)(10,467)(15,669)*(16,704)(15,301)(3,287)12,936*20,12519,54451,34659,126*63,65842,910
Interest income765920*857657554510*5678291,560890*——
Interest expense137*1071010*1079481,817*——
Other income (expense)723915*8431,149————————
Income tax expense (benefit)——(1,395)0*0*0*0522(55,987)42,426*17,04412,745
Net income (loss)(9,744)(14,754)*(14,466)(14,151)(2,777)13,464*20,64419,828108,56314,020*38,60125,988
Earnings per share, basic USD per share(0.17)(0.26)*(0.25)(0.25)(0.05)0.22*0.320.291.42—0.480.33
Earnings per share, diluted USD per share(0.17)(0.26)*(0.25)(0.25)(0.05)0.22*0.300.281.26—0.430.29
Weighted average shares, basic thousands of shares56,55357,394*57,50357,62158,82561,509*65,24467,92875,930—79,50978,444
Weighted average shares, diluted thousands of shares56,55357,394*57,50357,62158,82561,509*68,97571,91986,214—92,98592,479

Balance sheet

CSV

Fiscal quarters (CRMD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents53,31443,64335,18128,54135,28640,65166,286159,30948,493144,837178,087256,692
Short-term investments33,27332,38823,37117,07010,74411,03711,21731,4037,2243,69400
Marketable securities————————8,09110,364——
Accounts receivable———20617,38751,65454,61142,912158,574171,233154,807161,305
Inventory—2,1062,3204,0126,6497,6007,4889,63428,91729,71630,73138,583
Prepaid and other current assets1,1368822,1663,1392,9173,4825,1254,67616,32817,57119,48823,974
Total current assets89,06279,45063,41053,19473,154114,575144,862248,057259,535367,051383,113480,554
Property and equipment, net1,5891,8661,9061,9161,9001,8281,7281,6414,3475,9596,1667,852
Right-of-use asset6756406055685314934544143,1743,020——
Goodwill————————17,51530,00230,00230,002
Total assets91,42982,06068,02457,73177,586118,846149,583252,599750,861826,142815,637904,052
Accounts payable2,3864,2802,8263,3451,3441,7201,9335,81520,4547,88412,82710,238
Accrued liabilities5,1386,9706,5537,60816,97431,95232,28525,718109,092161,921112,773173,244
Total current liabilities7,67111,4019,53411,11118,48133,84034,39131,711133,644174,269128,776187,396
Lease liability, non-current5565174774353933493042582,4112,253——
Total liabilities8,22711,91810,01111,54718,87434,18934,69531,969376,732420,835378,588443,219
Accumulated deficit(306,946)(321,700)(336,166)(350,318)(353,094)(339,630)(318,986)(299,158)(190,595)(176,575)(137,974)(111,986)
Total stockholders' equity83,20270,14258,01346,18458,71284,657114,888220,630374,129405,307437,049460,833
Total liabilities and equity91,42982,06068,02457,73177,586118,846149,583252,599750,861826,142815,637904,052
Common shares outstanding (cover page) thousands of shares54,81254,98154,95955,86060,67765,18267,82574,64978,78979,05078,45277,944

Cash flows

CSV

Fiscal quarters (CRMD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(9,744)(14,754)*(14,466)(14,151)(2,777)13,464*20,64419,828108,56314,020*38,60125,988
Stock-based compensation1,003*1,217*2,4441,2641,2271,194*3,5002,6774,0663,589*4,5824,084
Depreciation and amortization——————162163*——10,54410,540*
Net cash from operating activities(8,697)*(10,746)*(17,310)(14,040)*(13,650)*(5,615)*19,73729,992*30,857*year only42,38286,237*
Purchases of property and equipment10*296*6135*10*10*1024*506*1,720*729561*
Net cash from investing activities(587)*598*8,9456,269*6,321*(304)*(195)(20,212)*(291,320)*3,297*2,965(561)*
Proceeds from issuing common stock0*434*——12,366*5,506*6,7620*0*1,026*00*
Proceeds from issuing equity——104,400—————————
Share repurchases——————00*——11,0926,392*
Net cash from financing activities42,899*468*(97)1,057*14,074*11,285*6,09383,242*150,531*(1,413)*(12,097)(7,071)*
Net change in cash33,612*(9,678)*(8,463)(6,715)*6,746*5,365*25,63593,023*(109,933)*96,344*33,25078,605*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
CorMedix256,692101,93186,237*77.9M— 10-QJun 30, 2026
Ardelyx46,317127,6552,171*251.4M— 10-QSep 30, 2026
Collegium Pharmaceutical129,467199,87871,323*32.6M— 10-QJun 30, 2026
Viridian Therapeutics172,86025,752not reported113.6M— 10-QSep 30, 2026
Akebia Therapeutics155,54849,1283,525*277.1M— 10-QJun 30, 2026
Intellia Therapeutics106,1287,659(83,113)*140.1M5.3 quarters 10-QJun 30, 2026
Geron62,64357,480(15,827)*642.5M4.0 quarters 10-QJun 30, 2026
Neogen172,000222,80012,900218.3M— 10-QAug 31, 2026
Wave Life Sciences197,31513,158(60,142)*197.2M7.4 quarters 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.